## FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| STATEMENT | <b>OF CHANGES IN</b> | BENEFICIAL | <b>OWNERSHIP</b> |
|-----------|----------------------|------------|------------------|
|           |                      |            |                  |

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Birznieks Gunther</u>  |   |  |                              |   |  | 2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [ VNDA ]            |                  |  |       |   |               |  |   |  | ionship of Reporting<br>all applicable)<br>Director               |   | 10% ( | Owner |
|--|---|--|------------------------------|---|--|--|------------------|--|-------|---|---------------|--|---|--|---|---|-------|-------|
| (Last) (First) (Middle) 2200 PENNSYLVANIA AVE NW, SUITE 300E   |   |  |                              |   |  | 3. Date of Earliest Transaction (Month/Day/Year) 01/02/2020                                |                  |  |       |   |               |  |   | X  | Officer (give title<br>below)<br>SVP, Business                    |   | below | ′ I   |
| (Street) WASHINGTON DC 20037 (City) (State) (Zip)  |   |  |                              | 4. 11   | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |                  |  |       |   |               |  | 3. Indivi<br>Line)<br>X   | ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person |   |   |       |       |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned                                    |  |                              |   |  |  |                  |  |       |   |               |  |   |  |   |   |       |       |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye   |   |  |                              |   | Execution Date,  |  | ite,             | 3. 4. Securities   |       | Acquired (A) or<br>(D) (Instr. 3, 4 and |               | d 5) Secu<br>Bene  |   | icially<br>d Following   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |       |       |
|  |   |  |                              |   |  |  |                  | Code   | v     | Amount                                  | (A) or<br>(D) | Price  |   | Transa   | action(s)<br>3 and 4)   |   | (     |       |
| Common Stock 01/02/202   |   |  |                              | 020   | 20   |  | S <sup>(1)</sup> |  | 4,020 | D                                       | \$15.92       | 5.9257(2)  |   | 47,231   | D   |   |       |       |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |  |                              |   |  |  |                  |  |       |   |               |  |   |  |   |   |       |       |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | Conversion or Exercise Price of Derivative Security  Date (Month/Day/Year)  Execution Date, if any (Month/Day/Year) |  | 4.<br>Transa<br>Code (<br>8) | (Instr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |  | 6. Date Exercisable and Expiration Date (Month/Day/Year)  Date Exercisable Expiration Date |                  | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Instr.<br>and 4)  Amoun<br>or<br>Number<br>of<br>Title Shares |       |   |               | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(<br>(Instr. 4) | Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)   |   |   |       |       |

## **Explanation of Responses:**

- 1. Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to a written election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.80 to \$16.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

## Remarks:

/s/ Gunther Birznieks

01/06/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.